Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Riccardo Casadei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9486-8190; OpenAlex author ID A5065743678, A5160380168. Sources: OpenAlex.

Their work

Papers
42 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
200
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 4 papers · 2024: 7 papers · 2025: 6 papers · 2026: 5 papers

Papers 42

  1. Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature. Last author DOI 10.1007/s13304-025-02382-z↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  4. The "Big short" of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. Last author DOI 10.1016/j.hpb.2025.10.014↗
  5. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  6. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  7. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  8. Stage IV pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastasis: are there survival benefits in liver resection? A systematic review and met… Last author DOI 10.1016/j.ejso.2025.109598↗
  9. Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer. Co-author DOI 10.1111/pcmr.13210↗
  10. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  11. Pancreatic cancer resection in the elderly: state of the art, and future challenges. A systematic review. Last author DOI 10.23736/s2724-5691.25.10527-3↗
  12. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  13. Clinicopathological predictive factors in long-term survivors who underwent surgery for pancreatic ductal adenocarcinoma: A single-center propensity score matc… Last author DOI 10.1002/wjs.12397↗
  14. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. Last author DOI 10.1016/j.hpb.2023.09.013↗
  15. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  16. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  17. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  18. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  19. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  20. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  21. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  22. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  23. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  24. Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre. Co-author DOI 10.1007/s13304-022-01346-x↗
  25. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  26. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Co-author DOI 10.1016/j.ejso.2021.01.001↗
  27. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087↗
  28. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  29. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  30. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. Co-author DOI 10.1007/s13304-020-00782-x↗
  31. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06718-3↗
  32. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  33. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). Co-author DOI 10.21873/anticanres.13975↗
  34. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  35. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  36. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  37. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. Co-author DOI 10.1259/bjrcr.20170086↗
  38. Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. Co-author DOI 10.3892/ijo.2018.4344↗
  39. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which… Co-author DOI 10.1007/s11605-015-2890-4↗
  40. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Co-author DOI 10.3892/mmr.2015.4344↗
  41. Locally advanced pancreatic cancer: open questions on terminology, diagnosis and management. Co-author DOI 10.1007/s13304-014-0258-z↗
  42. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Co-author DOI 10.3892/ol.2011.253↗

Closest collaborators

The 25 strongest of 200 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Claudio Ricci · 21 shared papers, 2014–2026 · strength 3.53
  2. Carlo Ingaldi · 13 shared papers, 2020–2026 · strength 2.65
  3. Vincenzo D’Ambra · 7 shared papers, 2024–2026 · strength 1.91
  4. Alessandro Zerbi · 10 shared papers, 2020–2026 · strength 1.42
  5. Roberto Salvia · 10 shared papers, 2021–2025 · strength 1.33
  6. Massimo Falconi · 10 shared papers, 2019–2024 · strength 1.16
  7. Ugo Boggi · 8 shared papers, 2020–2026 · strength 1.11
  8. Marc G. Besselink · 7 shared papers, 2020–2026 · strength 0.94
  9. Giuseppe Malleo · 7 shared papers, 2020–2024 · strength 0.93
  10. Mariacristina Di Marco · 12 shared papers, 2011–2022 · strength 0.91
  11. Sergio Alfieri · 5 shared papers, 2019–2026 · strength 0.74
  12. Emanuele F. Kauffmann · 4 shared papers, 2023–2026 · strength 0.72
  13. Francesco Minni · 9 shared papers, 2014–2022 · strength 0.69
  14. Gabriella Lionetto · 4 shared papers, 2024–2025 · strength 0.64
  15. Carla Serra · 7 shared papers, 2015–2022 · strength 0.59
  16. Giorgio Ercolani · 5 shared papers, 2015–2024 · strength 0.59
  17. Giovanni Butturini · 5 shared papers, 2020–2024 · strength 0.54
  18. Giuseppe Fusai · 3 shared papers, 2023–2026 · strength 0.52
  19. Giovanni Luigi Capretti · 4 shared papers, 2021–2025 · strength 0.52
  20. Mohammad Abu Hilal · 5 shared papers, 2020–2024 · strength 0.51
  21. Stefano Crippa · 3 shared papers, 2021–2024 · strength 0.50
  22. Matteo De Pastena · 4 shared papers, 2020–2024 · strength 0.49
  23. Fabio Casciani · 3 shared papers, 2024 · strength 0.49
  24. Bas Groot Koerkamp · 4 shared papers, 2021–2024 · strength 0.44
  25. Tobias Keck · 4 shared papers, 2020–2024 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.